| Literature DB >> 28515095 |
Hiroo Katsuya1,2, Mototsugu Shimokawa3, Kenji Ishitsuka1,4, Kazuhiro Kawai5, Masahiro Amano6, Atae Utsunomiya7, Ryosuke Hino8, Shuichi Hanada9, Tatsuro Jo10, Kunihiro Tsukasaki11, Yukiyoshi Moriuchi12, Eisaburo Sueoka13, Shinichiro Yoshida14, Hitoshi Suzushima15, Masaharu Miyahara16, Kiyoshi Yamashita17, Tetsuya Eto18, Junji Suzumiya19, Kazuo Tamura1.
Abstract
Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, sex, performance status, log10 (soluble interleukin-2 receptor [sIL-2R]), neutrophils count, and lymphadenopathy showed values of P < .05 in training samples. A multivariate analysis was performed on these factors, and only log10 (sIL-2R) was identified as an independent prognostic factor in training samples. Using a regression coefficient of this variable, a prognostic model was formulated to identify different levels of risk: indolent ATL-PI (iATL-PI) = 1.51 × log10 (sIL-2R [U/mL]). The values calculated by iATL-PI were divided into 3 groups using a quartile point. In the validation sample, median survival times (MSTs) were 1.6 years, 5.5 years, and not reached for patients in the high-, intermediate-, and low-risk groups, respectively (P < .0001). To make the scoring system clinically practicable, we simplified iATL-PI according to trichotomizing sIL-2R at 1000 and 6000 U/mL, using a quartile point. Patients with more than 6000 U/mL sIL-2R were categorized into the high-risk group, less than and equal to 1000 U/mL into the low-risk group, and the others into the intermediate-risk group, and MSTs were 1.6 years, not reached, and 5.5 years, respectively (P < .0001). iATL-PI has potential as a novel tool for a risk-adapted therapeutic approach.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28515095 DOI: 10.1182/blood-2017-01-757542
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113